butabarbital, calcium/magnesium/potassium/sodium oxybates. Possibly improves effects of another by pharmacodynamic synergism. Contraindicated. Coadministration with Alcoholic beverages or sedative hypnotics are contraindicated on account of additive CNS depression.
butabarbital will lower the extent or impact of sufentanil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unknown.
Teniposide: Barbiturates may possibly lessen the serum focus of Teniposide. Management: Take into consideration options to mixed treatment method with barbiturates and teniposide due to opportunity for diminished teniposide concentrations.
butabarbital will lessen the level or impact of bazedoxifene/conjugated estrogens by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
butabarbital will lower the level or impact of mestranol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
butabarbital will reduce the extent or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
butabarbital will lower the level or result of iloperidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
butabarbital will minimize the level or result of exemestane by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. For sufferers acquiring exemestane using a strong CYP3A4 inducer the advisable dose of exemestane is 50 mg everyday after a meal.
butabarbital will decrease the extent or result of methadone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
butabarbital will lessen the extent or influence of estropipate by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
butabarbital will decrease the extent or effect of etonogestrel by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
butabarbital will lessen the extent here or effect of ketoconazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unknown.
Utilizing this medication with any of the following medicines is not advised. Your medical professional may perhaps make a decision not to deal with you with this medication or modify several of the other medicines you are taking.
butabarbital will minimize the extent or outcome of vinblastine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Not known.